| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04593121 | Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIIB107 in Healthy Adult Participants | PHASE1 | COMPLETED | 84 | — | — | Oct 30, 2020 | Mar 5, 2024 | Apr 15, 2024 | 3 | United States |
An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. An SAE is any untoward medical occurrence that at any dose results in death, places the participant at immediate risk of death, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, results in a congenital anomaly/birth defect, or is a medically important event.
An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. An SAE is any untoward medical occurrence that at any dose results in death, places the participant at immediate risk of death, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, results in a congenital anomaly/birth defect, or is a medically important event.
| Arm | Type | Description |
|---|---|---|
| Cohort 1A | EXPERIMENTAL | Participants will receive Dose 1 of BIIB107 or placebo subcutaneous (SC) on Day 1. |
| Cohort 2A | EXPERIMENTAL | Participants will receive Dose 2 of BIIB107 or placebo SC on Day 1. |
| Cohort 3A | EXPERIMENTAL | Participants will receive Dose 3 of BIIB107 or placebo SC on Day 1. |
| Cohort 4A | EXPERIMENTAL | Participants will receive Dose 4 of BIIB107 or placebo SC on Day 1. |
| Cohort 7A | EXPERIMENTAL | Participants will receive Dose 5 of BIIB107 or placebo SC on Day 1. |
| Cohort 5A | EXPERIMENTAL | Participants will receive Dose 5 of BIIB107 or placebo intravenous (IV) on Day 1. |
| Cohort 8A | EXPERIMENTAL | Participants will receive Dose 6 of BIIB107 or placebo SC on Day 1. |
| Cohort 1B | EXPERIMENTAL | Participants will receive multiple doses of BIIB107 or placebo SC on approximately 4 dosing days. |
| Cohort 2B | EXPERIMENTAL | Participants will receive multiple doses of BIIB107 or placebo SC on approximately 4 dosing days. |
| Name | Type | Description |
|---|---|---|
| BIIB107 | DRUG | Administered as specified in the treatment arm. |
| Placebo | DRUG | Administered as specified in the treatment arm. |
Key Inclusion Criteria: * Must have a body mass index (BMI) between 18 and 30 kilogram per meter square (kg/m\^2), inclusive, and must weigh at least 55 kilogram (kg) * All women of childbearing potential must practice highly effective contraception during the study and for a period of 90 days, whi...